Cargando…

Risk factors and outcomes associated with persistent vancomycin resistant Enterococcal Bacteremia

BACKGROUND: Prior studies have identified that vancomycin resistant enterococcus (VRE) bacteremia that persists for four days or more is an independent predictor of mortality. Despite this, there is no published data to identify those patients at highest risk of developing persistent VRE bacteremia....

Descripción completa

Detalles Bibliográficos
Autores principales: Fox, Emily, Ha, David, Bounthavong, Mark, Meng, Lina, Mui, Emily, Holubar, Marisa, Deresinski, Stanley, Alegria, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9670444/
https://www.ncbi.nlm.nih.gov/pubmed/36384497
http://dx.doi.org/10.1186/s12879-022-07864-8
_version_ 1784832335650226176
author Fox, Emily
Ha, David
Bounthavong, Mark
Meng, Lina
Mui, Emily
Holubar, Marisa
Deresinski, Stanley
Alegria, William
author_facet Fox, Emily
Ha, David
Bounthavong, Mark
Meng, Lina
Mui, Emily
Holubar, Marisa
Deresinski, Stanley
Alegria, William
author_sort Fox, Emily
collection PubMed
description BACKGROUND: Prior studies have identified that vancomycin resistant enterococcus (VRE) bacteremia that persists for four days or more is an independent predictor of mortality. Despite this, there is no published data to identify those patients at highest risk of developing persistent VRE bacteremia. METHODS: This was a single center, retrospective, case-control study of adult patients with a VRE bloodstream infection (BSI). Case patients were those with persistent bacteremia (≥ 4 days despite VRE-directed therapy) and control patients were those with non-persistent bacteremia. Logistic regression was used to assess risk factors associated with persistent VRE BSIs. Secondary outcomes included in-hospital mortality, recurrent bacteremia, and breakthrough bacteremia. RESULTS: During the study period, 24/108 (22%) patients had persistently positive blood cultures. Risk factors for persistent bacteremia included severe neutropenia (OR 2.13), 4 out of 4 positive index blood cultures (OR 11.29) and lack of source control (OR 11.88). In an unadjusted analysis, no statistically significant differences in in-hospital mortality (58% versus 40%; p = 0.121), recurrent bacteremia (17% versus 6%; p = 0.090), or breakthrough bacteremia (13% versus 7%; p = 0.402) were observed between groups. CONCLUSION: Patients with severe neutropenia, 4 out of 4 positive index blood culture bottles, and lack of source control were more likely to develop persistent VRE bacteremia despite directed antibiotic treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-022-07864-8.
format Online
Article
Text
id pubmed-9670444
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-96704442022-11-18 Risk factors and outcomes associated with persistent vancomycin resistant Enterococcal Bacteremia Fox, Emily Ha, David Bounthavong, Mark Meng, Lina Mui, Emily Holubar, Marisa Deresinski, Stanley Alegria, William BMC Infect Dis Research BACKGROUND: Prior studies have identified that vancomycin resistant enterococcus (VRE) bacteremia that persists for four days or more is an independent predictor of mortality. Despite this, there is no published data to identify those patients at highest risk of developing persistent VRE bacteremia. METHODS: This was a single center, retrospective, case-control study of adult patients with a VRE bloodstream infection (BSI). Case patients were those with persistent bacteremia (≥ 4 days despite VRE-directed therapy) and control patients were those with non-persistent bacteremia. Logistic regression was used to assess risk factors associated with persistent VRE BSIs. Secondary outcomes included in-hospital mortality, recurrent bacteremia, and breakthrough bacteremia. RESULTS: During the study period, 24/108 (22%) patients had persistently positive blood cultures. Risk factors for persistent bacteremia included severe neutropenia (OR 2.13), 4 out of 4 positive index blood cultures (OR 11.29) and lack of source control (OR 11.88). In an unadjusted analysis, no statistically significant differences in in-hospital mortality (58% versus 40%; p = 0.121), recurrent bacteremia (17% versus 6%; p = 0.090), or breakthrough bacteremia (13% versus 7%; p = 0.402) were observed between groups. CONCLUSION: Patients with severe neutropenia, 4 out of 4 positive index blood culture bottles, and lack of source control were more likely to develop persistent VRE bacteremia despite directed antibiotic treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-022-07864-8. BioMed Central 2022-11-16 /pmc/articles/PMC9670444/ /pubmed/36384497 http://dx.doi.org/10.1186/s12879-022-07864-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Fox, Emily
Ha, David
Bounthavong, Mark
Meng, Lina
Mui, Emily
Holubar, Marisa
Deresinski, Stanley
Alegria, William
Risk factors and outcomes associated with persistent vancomycin resistant Enterococcal Bacteremia
title Risk factors and outcomes associated with persistent vancomycin resistant Enterococcal Bacteremia
title_full Risk factors and outcomes associated with persistent vancomycin resistant Enterococcal Bacteremia
title_fullStr Risk factors and outcomes associated with persistent vancomycin resistant Enterococcal Bacteremia
title_full_unstemmed Risk factors and outcomes associated with persistent vancomycin resistant Enterococcal Bacteremia
title_short Risk factors and outcomes associated with persistent vancomycin resistant Enterococcal Bacteremia
title_sort risk factors and outcomes associated with persistent vancomycin resistant enterococcal bacteremia
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9670444/
https://www.ncbi.nlm.nih.gov/pubmed/36384497
http://dx.doi.org/10.1186/s12879-022-07864-8
work_keys_str_mv AT foxemily riskfactorsandoutcomesassociatedwithpersistentvancomycinresistantenterococcalbacteremia
AT hadavid riskfactorsandoutcomesassociatedwithpersistentvancomycinresistantenterococcalbacteremia
AT bounthavongmark riskfactorsandoutcomesassociatedwithpersistentvancomycinresistantenterococcalbacteremia
AT menglina riskfactorsandoutcomesassociatedwithpersistentvancomycinresistantenterococcalbacteremia
AT muiemily riskfactorsandoutcomesassociatedwithpersistentvancomycinresistantenterococcalbacteremia
AT holubarmarisa riskfactorsandoutcomesassociatedwithpersistentvancomycinresistantenterococcalbacteremia
AT deresinskistanley riskfactorsandoutcomesassociatedwithpersistentvancomycinresistantenterococcalbacteremia
AT alegriawilliam riskfactorsandoutcomesassociatedwithpersistentvancomycinresistantenterococcalbacteremia